With two M&A deals expected to close in the second quarter, Gedeon Richter counts its wins and losses from a “solid” start to the year.
“A solid start of the year” is how Gedeon Richter described its performance during the first quarter of 2024. The Hungarian firm reported HUF200bn ($564m) in pharma revenues, which was a 12.6% year-on-year increase, with the CEO Gábor Orbán calling it a “milestone for one-quarter revenues.”
However, if it wasn’t for the ruble depreciation, the revenue growth could have been as high as 15.5%, Orbán explained....
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
